Home Search
viaskin - search results
If you're not happy with the results, please do another search
SnackSafely.com Newsletter: 2019/08/08
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut for the Treatment of Peanut Allergy (+4 Articles)
Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies
FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut...
The AAFA addresses concerns
regarding the Final Evidence Report released by the ICER.
ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not Yet Demonstrate That...
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Asthma and Allergy Foundation of America Elevates Patient Voice in ICER Review of New...
Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
Joint Statement on Peanut Allergy Therapy Review
Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.
Leading Allergists, Researchers and Food Allergy Advocates to Discuss State of ‘Food Oral Immunotherapy...
The summit intends to address the risks and benefits of OIT, OIT implementation in practice and the gaps in knowledge about OIT to enable physicians to have a better understanding of this therapy and to help patients make fully-informed choices about treatment options.
OIT is a Therapy, Not an Ideology
The decisions we all face as patients and caretakers depend on the individual, their allergies, their lifestyles and myriad other factors.
Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for Peanut Allergy
An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.
Milk and Peanut Clinical Trial Advances
Announcements regarding two food allergy therapies that are in or advancing toward clinical trials were made yesterday.
Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.
We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.
Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.
Please see our Terms of Service and Privacy Policy.
Copyright ©2011-2024 SnackSafely.com, Inc — All rights reserved